The Childhood Epilepsy drugs in development market research report provides comprehensive information on the therapeutics under development for Childhood Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Childhood Epilepsy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Childhood Epilepsy - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Childhood Epilepsy and features dormant and discontinued products.

GlobalData tracks 74 drugs in development for Childhood Epilepsy by 58 companies/universities/institutes. The top development phase for Childhood Epilepsy is preclinical with 35 drugs in that stage. The Childhood Epilepsy pipeline has 71 drugs in development by companies and three by universities/ institutes. Some of the companies in the Childhood Epilepsy pipeline products market are: EpyGenix Therapeutics, Bio-Pharm Solutions and Xenon Pharmaceuticals.

The key targets in the Childhood Epilepsy pipeline products market include Sodium Channel Protein Type 1 Subunit Alpha (Sodium Channel Protein Brain I Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.1 or SCN1A), Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA(A) Receptor or GABR), and 5-Hydroxytryptamine Receptor (Serotonin Receptor or 5 HT Receptor or HTR).

The key mechanisms of action in the Childhood Epilepsy pipeline product include Sodium Channel Protein Type 1 Subunit Alpha (Sodium Channel Protein Brain I Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.1 or SCN1A) Activator with ten drugs in Phase II. The Childhood Epilepsy pipeline products include nine routes of administration with the top ROA being Oral and seven key molecule types in the Childhood Epilepsy pipeline products market including Small Molecule, and Gene Therapy.

Childhood Epilepsy overview

Childhood epilepsy is a neurological disorder characterized by recurring seizures in children. Seizures result from abnormal electrical activity in the brain, causing temporary disruptions in behavior, awareness, sensation, or consciousness. This condition can manifest in various forms, from brief staring spells to convulsions or loss of consciousness. The causes of childhood epilepsy can vary, including genetic factors, brain injury, infections, developmental disorders, or unknown reasons in some cases. Diagnosis involves a comprehensive evaluation of medical history, physical exams, neurological tests, and sometimes imaging studies like electroencephalogram (EEG) to monitor brain activity.

For a complete picture of Childhood Epilepsy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.